Tonix Pharmaceuticals Holding Corp (TNXP):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C8184)
◆英語タイトル:Tonix Pharmaceuticals Holding Corp (TNXP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8184
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年10月
◆ページ数:64
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Tonix Pharmaceuticals Holding Corp (Tonix) is a developer of pharmaceutical products to address public health challenges. The company offers pharmaceutical products and treatments for disorders of the central nervous system including fibromyalgia, post traumatic stress disorder and episodic tension-type headache. Its products include oral formulation, smallpox vaccine, disintegrating sublingual tablets and tonmya. Tonix’s tonmya is a lead product candidate, designed as a bedtime treatment for post traumatic stress disorder. Its disintegrating sublingual tablets contain a dose and formulation of cyclobenzaprine and is used for the treatment of fibromyalgia and post-traumatic stress disorder. It markets its products through a network of distributors across the US. It has operations in Ireland, Canada and the US. Tonix is headquartered in New York, the US.

Tonix Pharmaceuticals Holding Corp (TNXP) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Tonix Pharmaceuticals Holding Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Tonix Pharmaceuticals Holding Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Tonix Pharmaceuticals Holding Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Tonix Pharmaceuticals Holding Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Tonix Pharmaceuticals Holding Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Tonix Pharmaceuticals Holding Corp, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Tonix Pharma Enters into Agreement with U.S. Army Medical Materiel Development Activity 12
Equity Offering 13
Tonix Pharma Plans to Raise up to USD75 Million in Public Offering of Securities 13
Tonix Pharma to Raise up to USD15 Million in Private Placement of Shares 14
Tonix Pharma Plans to Raise up to USD9 Million in Public Offering of Shares 16
Tonix Pharmaceuticals Holding Raises USD8 Million in Public Offering of Shares 17
Tonix Pharma Raises USD5.2 Million in Public Offering of Units 19
Tonix Pharma Raises Funds in Private Placement of Shares 21
Tonix Pharma Completes Underwriter’s Exercise of Over-Allotment Option of Public Offering of Shares for USD11.5 Million 22
Tonix Pharma Raises USD0.008 Million in Private Placement of Shares up on Exercise of Warrants 24
Tonix Pharma Raises USD20.1 Million in Public Offering of Shares 25
Tonix Pharma Raises USD28.7 Million in Public Offering of Shares 27
Tonix Pharma Raises USD0.12 Million in Private Placement of Shares up on Exercise of Warrants 29
Tonix Pharma Raises USD0.01 Million in Private Placement of Shares up on Exercise of Warrants 30
Tonix Pharma Raises USD0.16 Million in Private Placement of Shares up on Exercise of Warrants 31
Tonix Pharma Raises USD0.04 Million in Private Placement of Shares up on Exercise of Warrants 32
Tonix Pharma Raises USD0.02 Million in Private Placement of Shares up on Exercise of Warrants 33
Tonix Pharma Raises USD0.13 Million in Private Placement of Shares up on Exercise of Warrants 34
Tonix Pharma Raises USD0.006 Million in Private Placement of Shares up on Exercise of Warrants 35
Tonix Pharma Raises USD0.04 Million in Private Placement of Shares up on Exercise of Warrants 36
Tonix Pharma to Raise USD8 Million in Private Placement of Shares 37
Tonix Pharma Completes Public Offering Of Shares For US$43.5 Million 39
Tonix Pharma Completes Public Offering Of Units For US$11.4 Million 41
Tonix Pharma Completes Second Tranche Of Private Placement Of Units For US$1 Million 43
Tonix Pharma Completes Second Tranche Of Private Placement Of Units For US$2.3 Million 45
Debt Offering 46
Tonix Pharmaceuticals Completes Private Placement Of Notes Due 2013 For US$1 Million 46
Tonix Pharmaceuticals Holding Corp – Key Competitors 47
Tonix Pharmaceuticals Holding Corp – Key Employees 48
Tonix Pharmaceuticals Holding Corp – Locations And Subsidiaries 49
Head Office 49
Other Locations & Subsidiaries 49
Recent Developments 50
Financial Announcements 50
Aug 13, 2018: Tonix Pharmaceuticals reports second quarter 2018 financial results and operational highlights 50
May 14, 2018: Tonix Pharmaceuticals Announces First Quarter 2018 Financial Results 51
Mar 12, 2018: Tonix Pharmaceuticals Announces Fourth Quarter and Full Year 2017 Financial Results 52
Nov 07, 2017: Tonix Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Programs Update 54
Aug 14, 2017: Tonix Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Programs Update 56
Apr 17, 2017: Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Programs Update 58
Corporate Communications 60
Sep 07, 2018: Tonix Pharmaceuticals appoints Adeoye “Oye” Olukotun as Board Director 60
Feb 15, 2018: Tonix Pharmaceuticals Appoints David L. Grange to the Board of Directors 61
Jan 09, 2018: Tonix Pharmaceuticals Appoints Jessica Morris as Chief Operating Officer 62
Product News 63
01/10/2017: Tonix Pharmaceuticals Provides Update on TNX-601 at 9th Annual Biotech Showcase Conference 63
Appendix 64
Methodology 64
About GlobalData 64
Contact Us 64
Disclaimer 64

List of Tables
Tonix Pharmaceuticals Holding Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Tonix Pharmaceuticals Holding Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Tonix Pharmaceuticals Holding Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Tonix Pharmaceuticals Holding Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Tonix Pharmaceuticals Holding Corp, Deals By Therapy Area, 2012 to YTD 2018 9
Tonix Pharmaceuticals Holding Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Tonix Pharma Enters into Agreement with U.S. Army Medical Materiel Development Activity 12
Tonix Pharma Plans to Raise up to USD75 Million in Public Offering of Securities 13
Tonix Pharma to Raise up to USD15 Million in Private Placement of Shares 14
Tonix Pharma Plans to Raise up to USD9 Million in Public Offering of Shares 16
Tonix Pharmaceuticals Holding Raises USD8 Million in Public Offering of Shares 17
Tonix Pharma Raises USD5.2 Million in Public Offering of Units 19
Tonix Pharma Raises Funds in Private Placement of Shares 21
Tonix Pharma Completes Underwriter’s Exercise of Over-Allotment Option of Public Offering of Shares for USD11.5 Million 22
Tonix Pharma Raises USD0.008 Million in Private Placement of Shares up on Exercise of Warrants 24
Tonix Pharma Raises USD20.1 Million in Public Offering of Shares 25
Tonix Pharma Raises USD28.7 Million in Public Offering of Shares 27
Tonix Pharma Raises USD0.12 Million in Private Placement of Shares up on Exercise of Warrants 29
Tonix Pharma Raises USD0.01 Million in Private Placement of Shares up on Exercise of Warrants 30
Tonix Pharma Raises USD0.16 Million in Private Placement of Shares up on Exercise of Warrants 31
Tonix Pharma Raises USD0.04 Million in Private Placement of Shares up on Exercise of Warrants 32
Tonix Pharma Raises USD0.02 Million in Private Placement of Shares up on Exercise of Warrants 33
Tonix Pharma Raises USD0.13 Million in Private Placement of Shares up on Exercise of Warrants 34
Tonix Pharma Raises USD0.006 Million in Private Placement of Shares up on Exercise of Warrants 35
Tonix Pharma Raises USD0.04 Million in Private Placement of Shares up on Exercise of Warrants 36
Tonix Pharma to Raise USD8 Million in Private Placement of Shares 37
Tonix Pharma Completes Public Offering Of Shares For US$43.5 Million 39
Tonix Pharma Completes Public Offering Of Units For US$11.4 Million 41
Tonix Pharma Completes Second Tranche Of Private Placement Of Units For US$1 Million 43
Tonix Pharma Completes Second Tranche Of Private Placement Of Units For US$2.3 Million 45
Tonix Pharmaceuticals Completes Private Placement Of Notes Due 2013 For US$1 Million 46
Tonix Pharmaceuticals Holding Corp, Key Competitors 47
Tonix Pharmaceuticals Holding Corp, Key Employees 48
Tonix Pharmaceuticals Holding Corp, Other Locations 49
Tonix Pharmaceuticals Holding Corp, Subsidiaries 49

List of Figures
Tonix Pharmaceuticals Holding Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Tonix Pharmaceuticals Holding Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Tonix Pharmaceuticals Holding Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Tonix Pharmaceuticals Holding Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Tonix Pharmaceuticals Holding Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Tonix Pharmaceuticals Holding Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Tonix Pharmaceuticals Holding Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Tonix Pharmaceuticals Holding Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Tonix Pharmaceuticals Holding Corp (TNXP):製薬・医療:M&Aディール及び事業提携情報(Tonix Pharmaceuticals Holding Corp (TNXP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆